Since late 2019, COVID-19 has dominated global discussions as the third major coronavirus outbreak. SARS-CoV-2 infection presents an array of clinical findings from no symptoms at all to chronic pneumonia, mild flu-like illness, and fatal acute respiratory distress syndrome (ARDS). Globally, COVID-19 has infected 1900 persons every week since December 2022. The COVID-19 mortality rate has been 12,000 per week since the year began. Some people may be concerned about this report. Since the beginning of 2023, the weekly death toll has increased to 5900 in the United States and 2700 in Europe. There were rumours that the increased focus on creating more potent drugs was one of the factors delaying the release of COVID-19 vaccinations. Even yet, the world’s population would gain more from the earlier delivery of a less effective vaccine than from postponing the immunization campaign to wait for a more effective one. Though recent research has demonstrated that SARS-CoV-2 also has detrimental effects on other essential organs, the virus primarily damages the lungs by causing diffuse alveolar destruction with acute respiratory distress syndrome (ARDS), the brain, large intestine, spleen, kidney, and heart. WHO data published on March 28, 2022, shows that 196 vaccinations are undergoing preclinical testing and 153 vaccines have been authorized for clinical trials. These vaccines mostly consist of the following: VLP vaccines (4%), mRNA DNA vaccines (11%), protein subunit vaccines (34%), viral vector vaccines (both non-replication and replication; 17% of the total), live attenuated vaccines (1%), and RNA vaccines (18%). Despite their ability to lower infection risk and patient mortality, COVID-19 vaccines now have issues with decreasing the neutralizing activity of variants and adverse events linked to immunization. The effectiveness of vaccines may be increased, and the incidence of adverse effects may be substantially decreased by adopting mix-and-match vaccinations and creating new vaccines, such as virus-like particles and nanoparticle vaccines, enhancing current vaccine adjuvants, and altering the immunization route. The goal of the global COVID-19 vaccine campaign is to vaccinate as many people as possible to prevent the disease, decrease the rate of infection, minimize terrible outcomes, and allow individuals to return to their regular lives. The objective of the continent’s immunization campaign is to vaccinate. The current guidelines targeted at infectious agents need to be updated to prevent complete communities, groups, or individual isolation.